Latest news with #VikramPurohit
Business Insider
14 hours ago
- Business
- Business Insider
Ventyx Biosciences (VTYX) Gets a Hold from Stifel Nicolaus
In a report released today, from Stifel Nicolaus maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report), with a price target of $2.00. The company's shares closed last Friday at $2.26. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter In addition to Stifel Nicolaus, Ventyx Biosciences also received a Hold from Morgan Stanley's Vikram Purohit in a report issued on June 17. However, on June 18, Wells Fargo maintained a Buy rating on Ventyx Biosciences (NASDAQ: VTYX). VTYX market cap is currently $160.8M and has a P/E ratio of -1.29.
Yahoo
12-06-2025
- Business
- Yahoo
Axsome's AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 13 Biotech Stocks with Huge Upside Potential. The FDA's Division of Anesthesiology, Addiction Medicine, and Pain Medicine has issued a Refusal to File letter for Axsome Therapeutics, Inc. (NASDAQ:AXSM) AXS-14 new drug application. A pharmacist preparing a prescription for a rapidly absorbed multi-mechanistic medicine. The submission was deemed incomplete by the agency due to the use of an 8-week primary endpoint in one of the two supporting trials and a flexible-dose schedule. Vikram Purohit, an analyst at Morgan Stanley, stated that Axsome Therapeutics, Inc. (NASDAQ:AXSM) intends to start a fresh 12-week primary endpoint trial with a fixed dose in Q4. The stock is still rated as overweight by Morgan Stanley, which has set a price target of $190. AXS-14's regulatory setback is viewed as a temporary setback. The regulatory development of AXS-05 for Alzheimer's disease agitation and the commercial success of Auvelity in major depressive disorder are seen by Morgan Stanley as Axsome Therapeutics, Inc. (NASDAQ:AXSM)'s primary 2025 value drivers. The company is nevertheless optimistic about Axsome Therapeutics, Inc. (NASDAQ:AXSM)'s overall pipeline momentum and prospects for near-term revenue growth despite the AXS-14 filing struggle. Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical business in the clinical stage. It is involved in the development of new treatments for conditions of the central nervous system or CNS, for which there are few available options. The business is among the stocks with the biggest upside. While we acknowledge the potential of AXSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Sign in to access your portfolio
